🫀 Liver LI-RADS (CT/MRI HCC) Category
UseCategorise an observation on diagnostic CT/MRI in patients at high risk for HCC.
SourceACR LI-RADS v2018 CT/MRI. American College of Radiology
This-shift next steps
After scoring: open the scene pack, peer scores, and the matching pathway. Local reference — no HIS write.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
Methodology · worked example, guidelines & full notes
LI-RADS applies only to patients at high risk for HCC (cirrhosis, chronic HBV, prior HCC).
When to use
Categorise an observation on diagnostic CT/MRI in patients at high risk for HCC.
How it works
Major features — non-rim APHE, size, non-peripheral washout, enhancing capsule, threshold growth (≥ 50%/≤ 6 mo) — combine to LR-3/4/5. 10–19 mm + APHE + washout or threshold growth = LR-5.
Key points
- LI-RADS applies only to patients at high risk for HCC (cirrhosis, chronic HBV, prior HCC).
- LR-5 allows non-invasive HCC diagnosis without biopsy.
- LR-M (non-HCC malignancy) and LR-TIV (venous invasion) are adjudicated separately.
- Capsule alone vs washout/threshold-growth changes the category in the 10–19 mm + APHE band.
References
- [Guideline / primary source]ACR LI-RADS v2018 CT/MRI. American College of Radiology
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| At high risk for HCC (cirrhosis / chronic HBV / prior HCC) | Yes |
|---|---|
| Lesion size | 15 mm |
| Non-rim arterial-phase hyper-enhancement (APHE) | Yes |
| Non-peripheral washout | Yes |
| Enhancing capsule | Yes |
| Threshold growth (≥ 50% / ≤ 6 months) | Yes |
→CategoryLR-5
- Category：LR-5 (definite HCC)
- Read：Non-rim APHE present, size 15 mm, 3 additional major feature(s) (non-peripheral washout ✓, enhancing capsule ✓, threshold growth ✓)
- Management：Definite HCC: non-invasive imaging diagnosis without biopsy; multidisciplinary HCC staging and treatment (resection/ablation/transplant/transarterial/systemic)
| At high risk for HCC (cirrhosis / chronic HBV / prior HCC) | No |
|---|---|
| Lesion size | 15 mm |
| Non-rim arterial-phase hyper-enhancement (APHE) | No |
| Non-peripheral washout | No |
| Enhancing capsule | No |
| Threshold growth (≥ 50% / ≤ 6 months) | No |
→ApplicabilityLI-RADS not applicable
- Eligible population：Diagnostic CT/MRI LI-RADS applies only to patients at high risk for HCC: cirrhosis, chronic HBV, or current/prior HCC; not for age < 18, no risk factors, or cirrhosis from congenital hepatic fibrosis or vascular causes
- Advice：Evaluate liver lesions in non-at-risk patients along a general liver-lesion diagnostic pathway
- Basis：ACR LI-RADS v2018 CT/MRI diagnosis
Verification & sources · governance
FAQ
Frequently asked questions
- What are the limits and cautions when using Liver LI-RADS (CT/MRI HCC) Category?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- Does Liver LI-RADS (CT/MRI HCC) Category upload patient data? Where is it calculated?
- Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.